Key result
The 2013 international guidelines for thrombosis in cancer recommend individualized prophylaxis and treatment to address the widespread underutilization of venous thromboembolism management.
The review underscores the necessity of a multidisciplinary approach and adherence to the 2013 international guidelines for individualized VTE prophylaxis in cancer patients.
May support multidisciplinary adherence to 2013 cancer VTE guidelines; leaves open need for updated implementation trials.
Venous thromboembolism is a frequent and serious complication in patients with cancer. It is an independent prognostic factor of death in cancer patients and the second leading cause of death, but physicians often underestimate its importance, as well as the need for adequate prevention and treatment. Management of venous thromboembolism in patients with cancer requires the coordinated efforts of a wide range of clinicians, highlighting the importance of a multidisciplinary approach. However, a lack of consensus among various national and international clinical practice guidelines has contributed to knowledge and practice gaps among practitioners, and inconsistent approaches to venous thromboembolism. The 2013 international guidelines for thrombosis in cancer have sought to address these gaps by critically re-evaluating the evidence coming from clinical trials and synthesizing a number of guidelines documents. An individualized approach to prophylaxis is recommended for all patients.
No takes yet. Share an insight, caveat, or question.
Farge et al. (2014) conducted a review in Cancer-associated venous thromboembolism. The 2013 international guidelines for thrombosis in cancer recommend individualized prophylaxis and treatment to address the widespread underutilization of venous thromboembolism management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: